DEF 14A: Silexion Seeks Shareholder Approval for Capital Increase, Equity Plan

Silexion Therapeutics Corp. calls an extraordinary general meeting to approve a significant increase in authorized share capital and an expanded equity incentive plan to maintain Nasdaq listing and fund operations.

Summary

• An extraordinary general meeting will be held on March 16, 2026, to vote on two key proposals.
• Proposal 1 seeks to increase the authorized share capital by 50,000,000 ordinary shares, raising the total from 9,000,000 to 59,000,000 ordinary shares, each with a par value of US$0.0135.
• The primary purpose of the capital increase is to maintain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders' equity, and to fund the preclinical and clinical development of RNA interference (RNAi) therapies for KRAS mutations, as well as potential business development transactions.
• Currently, all 9,000,000 authorized ordinary shares are either issued or reserved for existing commitments, leaving no unissued shares available for future needs.
• Proposal 2 aims to amend the 2024 Equity Incentive Plan's evergreen provision, increasing the annual share addition from 5% of outstanding shares to a level that ensures the total equity incentive pool constitutes 10% of issued and outstanding shares on a fully diluted basis.
• This amendment is intended to enable the company to attract, retain, and motivate talented employees, officers, and directors in the highly competitive biotechnology industry.
• The Board of Directors unanimously recommends a vote FOR both the Authorized Share Capital Increase Proposal and the Evergreen Increase Proposal.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a necessary, albeit dilutive, step for Silexion to maintain its Nasdaq listing and secure future funding for critical R&D, reflecting a proactive approach to operational continuity and strategic development.

Positives

• Maintaining the Nasdaq listing is a critical asset, enhancing the price, liquidity, and trading market for securities, which is in the best interest of shareholders.
• Increased authorized capital provides essential flexibility for future financing activities and potential value-enhancing business development transactions, which can advance product candidates and complementary assets.
• An enhanced equity incentive plan is crucial for attracting, retaining, and motivating talented employees, officers, and directors in the competitive biotechnology sector.
• The proposed evergreen increase for the equity incentive plan aligns with the customary limit on dilution (10% of fully diluted shares) supported by institutional shareholder groups, indicating adherence to best practices.
• The potential conversion of the remaining $1,633,000 outstanding under the Moringa sponsor promissory note into equity would eliminate debt and increase shareholders' equity.

Negatives

• The increase in authorized share capital, while not immediately dilutive, will enable future transactions involving significant share issuances, which could result in substantial dilution to existing shareholders and a drop in the trading price per share.
• Resales of newly issued ordinary shares could cause the trading price to decrease, potentially jeopardizing compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00.
• Future issuances of shares could reduce shareholders' equity on a per-share basis.
• The newly available authorized shares could theoretically be used as an anti-takeover device, potentially limiting opportunities for shareholders to dispose of their ordinary shares at a premium.
• The increased size of the maximum annual evergreen increase under the 2024 Plan will lead to greater dilution for existing shareholders if and when equity awards are granted, vest, and are exercised.
• Shareholders will be unable to directly influence the size of future annual evergreen increases, as the mechanism is automatic, subject only to the Board's ability to reduce the annual increase.

Risks

• A substantial additional number of ordinary shares may be issued pursuant to various transactions, which could cause the price of the ordinary shares to decline and substantial dilution to existing shareholders.
• Resales of newly issued ordinary shares that become available for issuance may cause the trading price of ordinary shares to decrease, potentially jeopardizing compliance with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
• The anticipation that such issuances and resales may take place could make it more difficult to sell equity or equity-related securities in the future at a time and at a price that the company might otherwise wish to effect sales.
• Future issuance transactions could reduce shareholders' equity on a per-share basis.
• Shares issued from increased authorized share capital may have additional adverse effects on existing shareholders, including the potential to limit the opportunity for shareholders to dispose of their ordinary shares at a premium if used to resist a third-party transaction.
• The proposed change to the evergreen provision may lead to dilution of existing shareholders, who will be unable to influence the size of future increases under the Equity Pool.

Future Outlook

Silexion anticipates a critical period in the preclinical and clinical development of its innovative RNAi therapies to treat solid tumors driven by KRAS mutations. The company expects to pursue ongoing financing activities, including At-The-Market (ATM) sales, follow-on public offerings, and warrant exercises, to fund operations and maintain Nasdaq listing compliance. The increased share capital and expanded equity incentive plan are intended to provide the necessary flexibility and talent retention for long-term growth and value creation, with the Board aiming to manage share issuances selectively to support value enhancement and share price.

Management Comments

• "Our Nasdaq listing is a critical asset of our company and our shareholders, as it enhances the price and liquidity of, and the trading market for, our securities, and it is therefore in the best interest of our shareholders that we preserve it."
• "As we navigate the upcoming critical period in the pre-clinical and clinical development of our innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, we will need both sufficient funding and transactional flexibility for that development process."
• "The proposed increase of 50,000,000 additional authorized ordinary shares... represents the estimated minimum level needed to enable us to maintain Nasdaq listing compliance, while continuing to progress with our pre-clinical and clinical programs, and potential complementary opportunities, for the creation of shareholder value in the upcoming near-to-mid-term periods."
• "We intend to be as selective as possible before issuing share capital, to ensure that the terms of transactions in which we issue shares are consistent with our strategic goal of supporting value enhancement for our shareholders and buttressing the price of our ordinary shares."
• "We will carefully manage our enhanced authorized share capital to support and reinforce, as much as possible, the price and liquidity of, and the trading market for, our traded securities."
• "We believe that equity compensation is essential to attract and retain the talent necessary to execute our business strategy and create long-term shareholder value."
• "Our compensation committee and Board carefully review and approve all equity grants to ensure they are appropriate and aligned with shareholder interests, such that any dilution from those grants will be as minimal as possible."

Industry Context

StockSavvy.ai notes that Silexion Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on RNA interference (RNAi) therapies for solid tumors driven by KRAS mutations. This area is characterized by high research and development costs and a critical need for sustained funding and top talent. The company's proposals reflect common challenges in this industry, such as maintaining public listing requirements and offering competitive equity incentives to attract and retain specialized scientific and management personnel. The reliance on equity financing mechanisms like At-The-Market (ATM) programs and public offerings is typical for clinical-stage biotech companies.

Comparison to Industry Standards

• The proposed 10% equity incentive pool on a fully diluted basis aligns with the recommended limit espoused by institutional shareholder groups such as Institutional Shareholder Services (ISS) and Glass Lewis, indicating adherence to corporate governance best practices regarding dilution from equity compensation.
• Maintaining a Nasdaq listing, with its $2.5 million shareholders' equity requirement, is a standard for publicly traded companies, and Silexion's efforts to comply are typical for companies seeking to ensure market access and liquidity.
• The use of ATM programs, follow-on public offerings, and warrant exercises for financing is a common strategy for clinical-stage biotechnology companies to raise capital for R&D, similar to peers like Moderna (MRNA) or Alnylam Pharmaceuticals (ALNY) in their earlier stages, though the scale of Silexion's raises is smaller.

Corporate Governance

Related Party Transactions

• Conversion of remaining outstanding amounts under the Moringa sponsor promissory note ($1,633,000 currently outstanding) into newly issued ordinary shares. The Moringa sponsor, Moringa Sponsor, LP, and Greenstar, L.P. are affiliated with director Ilan Levin.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity issuances and equity incentive grants; risk of share price decline; benefit of maintaining Nasdaq listing and potential for long-term value creation if R&D and business development are successful.
• Employees, Officers, Directors, and Consultants: Enhanced ability to receive competitive equity compensation, aligning their interests with company growth and retention.
• Nasdaq: Compliance with listing rules maintained, ensuring continued trading on the exchange.
• Creditors: Conversion of the Moringa sponsor promissory note would reduce the company's debt.

Next Steps

• Shareholders are to vote on the Authorized Share Capital Increase Proposal and the Evergreen Increase Proposal at the extraordinary general meeting on March 16, 2026.
• If approved, the Board intends to carefully manage the use of the increased authorized share capital with a view toward minimizing unnecessary dilution to existing shareholders, while balancing the company's capital needs.
• If approved, the change to the evergreen provision will be effective as of January 1, 2026, resulting in an immediate increase of 594,900 ordinary shares to the 2024 Plan Share Pool.
• Ongoing preclinical and clinical development of the SIL204 product candidate.
• Potential acquisitions of assets that are complementary to the company's RNAi therapies.
• Ongoing sales of newly issued ordinary shares under the ATM program.
• Potential follow-on public offerings and exercises of warrants.

Key Dates

Recommendation

The proposals are crucial for Silexion to maintain its Nasdaq listing and secure necessary funding for its critical RNAi therapy development. While the potential for significant dilution is a concern, these actions are defensive and essential for the company's operational continuity and long-term strategic goals. Investors should hold to observe the execution of these plans and the progress of their clinical programs, weighing the necessity of these measures against the inherent dilution risks.

Keywords

Silexion Therapeutics, SEC filing, DEF 14A, proxy statement, authorized share capital, equity incentive plan, Nasdaq listing, shareholder equity, dilution, RNAi therapies, KRAS mutations, biotechnology, corporate governance, capital raise, stock price, warrants, ATM financing